Thumbnail

DIABETIC MACULAR EDEMA MARKET - PIPELINE INTELLIGENCE, 2020

Looking to buy the report?

Introduction

Diabetic macular edema is among the most common cause of vision loss for diabetic patients. It is mainly identified as the result of hyper-permeability of the retinal vasculature. Macular edema is linked with diabetic retinopathy severity. The causes of diabetic macular edema are multifactorial, which require understanding the pathogenesis and molecular pathways involved in the development of the disease. Pharmaceutical companies in recent years have targeted combinations of several therapies, towards different pathways or different steps of the same pathway, for the treatment of DME. Some established treatments are aimed at maintaining the patient’s vision and reducing future vision loss through medication and laser surgery.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises of a list of key sponsors with pipeline products for the concerned market.

Diabetic Macular Edema Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for diabetic macular edema indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Diabetic Macular Edema Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information of registered clinical trials in different countries, across several developed and emerging markets
  • A growing number of patient visits to hospitals for eye treatment, multiple physiological features for assessment, such as angiogenesis, inflammation, and oxidative stress, enhancements in diagnostics procedures for early identification of the disease, and high investments in research activities drive the pipeline for diabetic macular edema

Key Sponsors in Diabetic Macular Edema Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide

  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy